Did you move up your Semaglutide or Tirzepatide dose every 4 weeks on the dot, or stay on the lowest dose that was still working?
When I first started GLP-1 therapy, I thought you were required to increase the dose every 4 weeks like a race to the maximum pen strength. When I jumped from 0.5 mg to 1.0 mg right at week 8, the nausea and sulfur burps hit me hard for two days after each injection, and I could barely eat 900 calories. My obesity-medicine doctor told me that clinical trials used fixed 4-week escalations for protocol uniformity, but in real-world practice she keeps patients on any dose that is delivering steady 1–1.5 lb/week loss and quiet food noise with zero nausea. I ended up staying at 0.5 mg for 10 weeks and 1.0 mg for 12 weeks—and lost 34 lbs with almost zero GI side effects. How long did you stay on each dose tier, and what told you it was truly time to move up?
FDA labeling for Wegovy (semaglutide) and Zepbound (tirzepatide) permits delaying dose escalation by 4+ weeks if gastrointestinal side effects occur, and clinical obesity societies endorse maintaining the lowest effective dose that achieves glycemic and cardiometabolic targets.